Episode Details
Back to EpisodesAldeyra Resubmits NDA for DED Drug Reproxalap
Published 1 year, 7 months ago
Description
Aldeyra resubmits its NDA for dry eye drug reproxalap; Clearside announces new phase 2b topline data for its investigational extended-release wet AMD drug; and Bausch + Lomb launches a new digital e-commerce marketplace.
Learn more about your ad choices. Visit megaphone.fm/adchoices